Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
488 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT04598724 | Addressing Barriers to Palliative Care Use in Bladder Cancer | completed | — | 54 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 3, 2023 |
| clinicaltrials |
| NCT02708381 | Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database | completed | — | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03078348 | Increasing Access to Colorectal Cancer Testing (IACCT) for Blacks(IACCT) | completed | N/A | 331 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02722941 | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | terminated | Phase 2 | 5 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01795586 | A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT01662609 | Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer | completed | — | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02218164 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02440425 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03834623 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT02960620 | Therasphere for Unresectable Primary or Secondary Liver Neoplasia | no longer available | — | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01776723 | A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT01804179 | Colorectal Cancer Awareness, Research, Education and Screening (CARES) | completed | N/A | 514 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT02015936 | Physical Activity for Advanced Stage Cancer Patients | completed | N/A | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT02935309 | Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT03874325 | Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04055688 | Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | terminated | Phase 2 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | completed | Phase 1 / Phase 2 | 55 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT02586675 | TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT01599520 | Stress Management Training for Latinas Receiving Chemotherapy | completed | N/A | 140 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02592447 | Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention | completed | N/A | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT01054144 | Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02115542 | Single Agent Regorafenib in Refractory Advanced Biliary Cancers | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01672944 | Evaluating Biobanking Educational Tools | completed | N/A | 339 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03176576 | Patient Navigation in the Adolescent and Young Adult (AYA) Cancer Population | completed | N/A | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT01630161 | Smoking Relapse-Prevention Intervention for Cancer Patients | completed | N/A | 441 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT02138383 | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | completed | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT02328807 | Focal Prostate Radio-Frequency Ablation | completed | N/A | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02631590 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT02948946 | Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors | completed | — | 105 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | terminated | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT00816985 | Liposuction for Arm Lymphedema Following Breast Cancer Surgery | completed | N/A | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT01842646 | Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT02981797 | Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 | completed | — | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02292173 | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01497496 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02155088 | BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03718650 | Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02139358 | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | completed | Phase 1 / Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02187822 | Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases | terminated | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials